News And Announcements
Destiny Pharma upbeat on recent study into mupirocin alternative
Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent “strong support” for the potential of its ‘XF-73’ nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.
ReNeuron treats first Oxford patient as part of expanded study
Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.
Aquaculture firm Benchmark ends year ahead of market forecasts
Aquaculture biotechnology company Benchmark said in a trading update on Monday that, after positive financial results in its third quarter, it had maintained that momentum through the final three months of the financial year, delivering a “stronger-than-expected” trading performance across its three business areas.
National Grid performs in line with H1 expectations
Utilities firm National Grid said on Monday that it had continued to perform in line with expectations ahead of the release of its first-half results on 18 November.
ContourGlobal appoints new head of Investor Relations
ContourGlobal said on Monday that it has appointed Jose Cano as senior vice president of Investor Relations.
LondonMetric buys two London logistics assets for £20.2m
LondonMetric Property has bought two last mile logistics assets in Fulham and Tottenham for a combined £20. 2m.
Tesco starts £500m share buyback
British supermarket giant Tesco on Monday said it had started its planned buyback of up to £500m in shares.